Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate ...(e notice that we received from the FDA i...),Health

As of December 31, 2007, Genta had no long-term debt, $0.5 million in short-term debt, and had cash, cash equivalents and marketable securities of $7.8 million. At December 31, 2006, the Company had no long-term debt, $0.6 million in short-term debt, and had cash, cash equivalents and marketable securities of $29.5 million. Net cash used in operating activities through December 31, 2007 was $31.7 million. As a subsequent event, on February 13, 2008 the Company closed a registered stock offering with institutional investors and sold 6 million shares of common stock for gross proceeds totaling approximately $3.1 million before fees and expenses.

Conference Call and Webcast

Genta management will host a conference call and live audio webcast to discuss financial results and general corporate activities on March 12, 2008 at 8:00 am EDT.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (706) 679-3140 (international). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.

For investors unable to participate in the live call, a replay will be available approximately two hours after the completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 35508613.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen
'/>"/>